Sheng Chen

Jiangxi Provincial Key Laboratory Of Drug Target Discovery And Validation
Nanchang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Asprosin attenuates diabetic cardiomyopathy through inhibiting autophagy mediated by AMPK/mTOR/ULK1 pathway.

Asprosin attenuates diabetic cardiomyopathy through inhibiting autophagy mediated by AMPK/mTOR/ULK1 pathway.

Journal: American journal of physiology. Cell physiology

Published: June 25, 2025

Osteopontin aggravates myocardial fibrosis by promoting phenotypic transition of cardiac fibroblasts via Hippo-YAP pathway.

Osteopontin aggravates myocardial fibrosis by promoting phenotypic transition of cardiac fibroblasts via Hippo-YAP pathway.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: April 23, 2025

Asprosin Aggravates Tubular Epithelial Cell Injury and Phenotypic Transformation via Mitochondrial Dynamics Disorder Mediated by Excessive Drp1 SUMOylation in Diabetic Nephropathy Mice.

Asprosin Aggravates Tubular Epithelial Cell Injury and Phenotypic Transformation via Mitochondrial Dynamics Disorder Mediated by Excessive Drp1 SUMOylation in Diabetic Nephropathy Mice.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 20, 2025

Correction: Yin et al. Angiogenesis-Browning Interplay Mediated by Asprosin-Deficiency Contributes to Weight Loss in Mice with Obesity. Int. J. Mol. Sci. 2022, 23, 16166.

Correction: Yin et al. Angiogenesis-Browning Interplay Mediated by Asprosin-Deficiency Contributes to Weight Loss in Mice with Obesity. Int. J. Mol. Sci. 2022, 23, 16166.

Journal: International journal of molecular sciences

Published: December 04, 2024

Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species.

Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species.

Journal: Drug development research

Published: October 04, 2023

Asprosin contributes to pathogenesis of obesity by adipocyte mitophagy induction to inhibit white adipose browning in mice.

Asprosin contributes to pathogenesis of obesity by adipocyte mitophagy induction to inhibit white adipose browning in mice.

Journal: International journal of obesity (2005)

Published: August 08, 2023

Angiogenesis-Browning Interplay Mediated by Asprosin-Knockout Contributes to Weight Loss in Mice with Obesity.

Angiogenesis-Browning Interplay Mediated by Asprosin-Knockout Contributes to Weight Loss in Mice with Obesity.

Journal: International journal of molecular sciences

Published: November 12, 2022

Acacetin alleviates energy metabolism disorder through promoting white fat browning mediated by AC-cAMP pathway.

Acacetin alleviates energy metabolism disorder through promoting white fat browning mediated by AC-cAMP pathway.

Journal: Journal of physiology and biochemistry

Published: August 25, 2022

Asprosin Exacerbates Endothelium Inflammation Induced by Hyperlipidemia Through Activating IKKβ-NF-κBp65 Pathway.

Asprosin Exacerbates Endothelium Inflammation Induced by Hyperlipidemia Through Activating IKKβ-NF-κBp65 Pathway.

Journal: Inflammation

Published: July 30, 2022

Asprosin aggravates vascular endothelial dysfunction via disturbing mitochondrial dynamics in obesity models.

Asprosin aggravates vascular endothelial dysfunction via disturbing mitochondrial dynamics in obesity models.

Journal: Obesity (Silver Spring, Md.)

Published: June 08, 2022

The discrepancy between the absence of copper deposition and the presence of neuronal damage in the brain of Atp7b(-/-) mice.

The discrepancy between the absence of copper deposition and the presence of neuronal damage in the brain of Atp7b(-/-) mice.

Journal: Metallomics : integrated biometal science

Published: January 17, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026